These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 32114889

  • 1. Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies.
    Toth PP, Jones SR, Monsalvo ML, Elliott-Davey M, López JAG, Banach M.
    J Am Heart Assoc; 2020 Mar 03; 9(5):e014129. PubMed ID: 32114889
    [Abstract] [Full Text] [Related]

  • 2. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
    Lorenzatti AJ, Monsalvo ML, López JAG, Wang H, Rosenson RS.
    Cardiovasc Diabetol; 2021 Apr 30; 20(1):94. PubMed ID: 33941192
    [Abstract] [Full Text] [Related]

  • 3. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK, Del Prato S, Müller-Wieland D, Cariou B, Colhoun HM, Tinahones FJ, Domenger C, Letierce A, Mandel J, Samuel R, Bujas-Bobanovic M, Leiter LA.
    Cardiovasc Diabetol; 2019 Nov 09; 18(1):149. PubMed ID: 31706300
    [Abstract] [Full Text] [Related]

  • 4. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
    Colhoun HM, Leiter LA, Müller-Wieland D, Cariou B, Ray KK, Tinahones FJ, Domenger C, Letierce A, Israel M, Samuel R, Del Prato S.
    Cardiovasc Diabetol; 2020 Feb 08; 19(1):14. PubMed ID: 32035487
    [Abstract] [Full Text] [Related]

  • 5. Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials.
    Bays HE, Leiter LA, Colhoun HM, Thompson D, Bessac L, Pordy R, Toth PP.
    J Am Heart Assoc; 2017 Aug 08; 6(8):. PubMed ID: 28862926
    [Abstract] [Full Text] [Related]

  • 6. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
    Taskinen MR, Björnson E, Kahri J, Söderlund S, Matikainen N, Porthan K, Ainola M, Hakkarainen A, Lundbom N, Fermanelli V, Fuchs J, Thorsell A, Kronenberg F, Andersson L, Adiels M, Packard CJ, Borén J.
    Arterioscler Thromb Vasc Biol; 2021 Feb 08; 41(2):962-975. PubMed ID: 33356392
    [Abstract] [Full Text] [Related]

  • 7. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
    Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CP.
    Atherosclerosis; 2019 Sep 08; 288():194-202. PubMed ID: 31253441
    [Abstract] [Full Text] [Related]

  • 8. Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications.
    Wasserman SM, Sabatine MS, Koren MJ, Giugliano RP, Legg JC, Emery MG, Doshi S, Liu T, Somaratne R, Gibbs JP.
    J Cardiovasc Pharmacol Ther; 2018 Sep 08; 23(5):423-432. PubMed ID: 29768954
    [Abstract] [Full Text] [Related]

  • 9. Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.
    Boccara F, Kumar PN, Caramelli B, Calmy A, López JAG, Bray S, Cyrille M, Rosenson RS, BEIJERINCK Investigators.
    J Am Coll Cardiol; 2020 May 26; 75(20):2570-2584. PubMed ID: 32234462
    [Abstract] [Full Text] [Related]

  • 10. Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.
    Henry RR, Müller-Wieland D, Taub PR, Bujas-Bobanovic M, Louie MJ, Letierce A, Ginsberg HN.
    Diabetes Obes Metab; 2018 Jul 26; 20(7):1632-1641. PubMed ID: 29493859
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial.
    Taskinen MR, Del Prato S, Bujas-Bobanovic M, Louie MJ, Letierce A, Thompson D, Colhoun HM.
    Atherosclerosis; 2018 Sep 26; 276():124-130. PubMed ID: 30059843
    [Abstract] [Full Text] [Related]

  • 12. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
    Nissen SE, Dent-Acosta RE, Rosenson RS, Stroes E, Sattar N, Preiss D, Mancini GB, Ballantyne CM, Catapano A, Gouni-Berthold I, Stein EA, Xue A, Wasserman SM, Scott R, Thompson PD, GAUSS-3 Investigators.
    Clin Cardiol; 2016 Mar 26; 39(3):137-44. PubMed ID: 26946077
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
    Kereiakes DJ, Lepor NE, Gerber R, Veronica Lee L, Elassal J, Thompson D, Michael Gibson C.
    Atherosclerosis; 2018 Oct 26; 277():211-218. PubMed ID: 30025648
    [Abstract] [Full Text] [Related]

  • 14. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.
    Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, Somaratne R, Raal FJ.
    JAMA Cardiol; 2017 Jun 01; 2(6):598-607. PubMed ID: 28291870
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E, Salvetti M.
    High Blood Press Cardiovasc Prev; 2016 Sep 01; 23(3):217-30. PubMed ID: 27567901
    [Abstract] [Full Text] [Related]

  • 17. Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial.
    Lorenzatti AJ, Eliaschewitz FG, Chen Y, Lu J, Baass A, Monsalvo ML, Wang N, Hamer AW, Ge J.
    Diabetes Obes Metab; 2019 Jun 01; 21(6):1455-1463. PubMed ID: 30821053
    [Abstract] [Full Text] [Related]

  • 18. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
    Santos RD, Ruzza A, Hovingh GK, Wiegman A, Mach F, Kurtz CE, Hamer A, Bridges I, Bartuli A, Bergeron J, Szamosi T, Santra S, Stefanutti C, Descamps OS, Greber-Platzer S, Luirink I, Kastelein JJP, Gaudet D, HAUSER-RCT Investigators.
    N Engl J Med; 2020 Oct 01; 383(14):1317-1327. PubMed ID: 32865373
    [Abstract] [Full Text] [Related]

  • 19. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
    Ray KK, Stoekenbroek RM, Kallend D, Leiter LA, Landmesser U, Wright RS, Wijngaard P, Kastelein JJP.
    Circulation; 2018 Sep 25; 138(13):1304-1316. PubMed ID: 29735484
    [Abstract] [Full Text] [Related]

  • 20. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
    Hollstein T, Vogt A, Grenkowitz T, Stojakovic T, März W, Laufs U, Bölükbasi B, Steinhagen-Thiessen E, Scharnagl H, Kassner U.
    Vascul Pharmacol; 2019 May 25; 116():8-15. PubMed ID: 30910670
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.